Our lead product candidate, Qutenza™ (NGX-4010), is a dermal high-concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions. A single 30- or 60-minute Qutenza patch application directly to the site of the pain may provide up to three months of relief from neuropathic pain, with minimum side effects.
In March 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion, recommending the approval of our marketing authorization application (MAA) for Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. We are currently awaiting the European Commission's decision on the CHMP's opinion, a process which normally takes approximately 60 to 90 days. We have also submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Qutenza for post-herpetic neuralgia (PHN).
Learn more about QUTENZA™
What is Neuropathic Pain?
